Emerging Growth Patterns Driving Rapid Expansion in the Human Liver Model Market

The human liver model market is poised for significant expansion as advancements in biotechnology and drug development continue to accelerate. Growing emphasis on precision toxicology and innovative testing methods is driving demand for more accurate and human-relevant liver models. This overview explores the market's anticipated value, influential players, key trends, and the main segments shaping its growth.

Forecasting the Human Liver Model Market Value by 2030
The market for human liver models is expected to experience rapid growth, reaching a valuation of $5.02 billion by 2030. This represents a compound annual growth rate (CAGR) of 14.0%. The expansion is fueled by rising demand for precise toxicology testing platforms, broader adoption of organ-on-chip technologies, and an increased regulatory push to reduce animal testing. Additionally, greater investments in sophisticated in vitro research tools and the preference for human-relevant models early in drug development are driving growth. Key trends include the rising use of advanced in vitro liver models for toxicity assessment, the integration of liver organoids in drug discovery processes, and the expanding applications of liver-on-a-chip technology within preclinical research. These developments collectively enhance predictive hepatotoxicity evaluation and support safer drug design.

Download a free report of the human liver model market report:
https://www.thebusinessresearchcompany.com/report/human-liver-model-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Human Liver Model Industry
Several prominent firms are shaping the human liver model market, including Corning Incorporated, EISCO Scientific LLC, BioIVT LLC, Cyprotex plc, Emulate Inc., Cellink AB, Nortis Inc., InSphero AG, CN Bio Innovations Ltd., TissUse GmbH, HemoShear Therapeutics Inc., Cyfuse Biomedical, MIMETAS BV, Biopredic International Sarl, ZenBio, Hurel Corporation, Regenovo, Pandorum, Organovo Holdings Inc., BICO Group, Hepregen Corporation, Kirkstall Ltd., HepaLife Technologies Inc., and Cellaïon SA.

In a notable development, AnaBios Corporation, a biotechnology research company, acquired Cell Systems in April 2023 for an undisclosed sum. This strategic acquisition aims to strengthen AnaBios' drug discovery capabilities by incorporating Cell Systems' advanced cell-based technologies. The deal enhances AnaBios' portfolio of human-relevant models, improving their ability to predict drug safety and efficacy more accurately. Cell Systems is headquartered in the United States and specializes in biotechnology research.

View the full human liver model market report:
https://www.thebusinessresearchcompany.com/report/human-liver-model-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends and Opportunities in the Human Liver Model Sector
There is a growing focus among market leaders on leveraging deep learning technologies to improve nuclear imaging devices and equipment. Deep learning, a branch of artificial intelligence, utilizes neural networks trained on extensive datasets to enhance image quality, reduce noise, and enable more precise quantitative analysis. For example, in May 2023, GE HealthCare, a U.S.-based medical technology company, obtained FDA 510(k) clearance for its Precision DL software tailored for the Omni Legend PET/CT system. This AI-powered tool delivers an average 11% improvement in contrast recovery, a 23% increase in contrast-to-noise ratio, a 42% boost in detecting small low-contrast lesions, and a 14% increase in quantitative accuracy. These enhancements facilitate earlier diagnosis and more confident clinical decisions.

The Largest Market Segments within Human Liver Models
The human liver model market is categorized into several key segments:
1) By Product Type: Liver Organoids, Liver-On-A-Chip, 2D Models, and 3D Bioprinting.
2) By Application: Educational use, Drug Discovery, and Other Applications.
3) By End Users: Research Institutes, Pharmaceutical Companies, and Other End Users.

Further subcategories include:
- Liver Organoids: Primary Liver Organoids and Induced Pluripotent Stem Cell (iPSC)-Derived Organoids.
- Liver-On-A-Chip: Microfluidic Liver Chips and Multi-Organ Chip Systems.
- 2D Models: Liver Cell Cultures and Liver Cell Lines.
- 3D Bioprinting: Bioprinted Liver Tissues and Hybrid Bioprinted Models.

These segments highlight the diverse range of products and applications driving innovation and adoption in the human liver model market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.